

Validation data for Raji-hOX40 Cells

<https://www.invivogen.com/raji-hox40>

For research use only

Version 20L15-ED

Raji-hOX40 cells were developed from the Raji cell line to overexpress the human OX40 gene. Raji-hOX40 cells were designed as target cells in InvivoGen's antibody-dependent cellular cytotoxicity (ADCC) assay using clinically-relevant anti-human OX40 monoclonal antibodies (mAbs). Human OX40 expression by Raji-hOX40 cells has been verified by flow-cytometry (Figure 1), and induction of ADCC has been validated using a collection of anti-human OX40 antibody isotypes and Jurkat-Lucia™ NFAT-CD16 reporter cells (Figure 2). The level of ADCC induction is measured by an NFAT-dependent Lucia luciferase reporter protein. Antibodies displaying lower EC₅₀ have higher ADCC potency.

Validation of OX40 expression by flow cytometry




Figure 1: Validation of the expression of human OX40 by Raji-hOX40 cells. Raji-Null (A) and Raji-hOX40 (B) cells were incubated with a PE-conjugated Anti-hOX40 mAb for 30 minutes. The binding affinity was then measured using flow cytometry.

ADCC assay using various anti-human OX40 antibody isotypes and Raji-hOX40 target cells




Figure 2: Comparison of ADCC potency for native and engineered anti-human OX40 antibody isotypes. Raji-hOX40 cells were incubated with gradient concentrations of Anti-hOX40 or Anti-β-galactosidase (β-Gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com

 **InvivoGen**
www.invivogen.com